Eye­Point sells re­main­ing rights to eye im­plant, piv­ots to tack­le an­ti-VEG­Fs

Eye­Point is sell­ing off the re­main­ing glob­al rights to its in­trav­it­re­al im­plant Yu­tiq to Al­imera, an­oth­er eye-fo­cused biotech, for $82.5 mil­lion.

Eye­Point Phar­ma­ceu­ti­cals an­nounced Thurs­day that Al­imera will re­ceive glob­al rights to Yu­tiq ex­cept in Chi­na, Hong Kong, Tai­wan, Macau and South­east Asia. Eye­Point, in 2018, grant­ed an ex­clu­sive li­cense to Oc­u­men­sion Ther­a­peu­tics, a Chi­nese biotech in those mar­kets. Eye­Point con­tin­ues to re­ceive roy­al­ties from those sales — and ex­pects to keep them for at least the next decade.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN